Eyenovia, Inc. announced on September 27, 2024, the pricing of a registered direct offering totaling approximately $4 million in gross proceeds. The company entered into a securities purchase agreement with a healthcare-focused institutional investor.
The offering involves the purchase and sale of 8,695,653 shares of common stock, or common stock equivalents, and warrants to purchase an equal number of shares. The combined offering price is $0.46 per share and accompanying warrant, with warrants exercisable at $0.50 per share.
Net proceeds from this offering are designated to fund commercialization activities for Mydcombi and clobetasol propionate, complete the CHAPERONE pediatric myopia clinical study, and for working capital and general corporate purposes, including potential repayment of existing indebtedness.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.